Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Calculating future 10-year breast cancer risks in risk-adapted surveillance: A method comparison and application in clinical practice.
Zachariae S, Quante AS, Kiechle M, Rhiem K, Fehm TN, Schröder JG, Horvath J, Leinert E, Dikow N, Ronez J, Schönfeld M, van Mackelenbergh MT, Schatz UA, Meisel C, Aktas B, Witt D, Mehraein Y, Weber BHF, Solbach C, Speiser D, Hoyer J, Faigle-Krehl G, Much CD, Mueller-Rausch AV, Villavicencio-Lorini P, Banys-Paluchowski M, Pieh D, Schmutzler RK, Fischer C, Engel C. Zachariae S, et al. Among authors: van mackelenbergh mt. Cancer Prev Res (Phila). 2024 Nov 22. doi: 10.1158/1940-6207.CAPR-24-0328. Online ahead of print. Cancer Prev Res (Phila). 2024. PMID: 39575650
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer.
O'Regan RM, Zhang Y, Fleming GF, Francis PA, Kammler R, Viale G, Dell'Orto P, Lang I, Bellet M, Bonnefoi HR, Tondini C, Villa F, Bernardo A, Ciruelos EM, Neven P, Karlsson P, Müller B, Jochum W, Zaman K, Martino S, Geyer CE Jr, Jerzak KJ, Davidson NE, Coleman RE, Ingle JN, van Mackelenbergh MT, Loi S, Colleoni M, Schnabel CA, Treuner K, Regan MM. O'Regan RM, et al. Among authors: van mackelenbergh mt. JAMA Oncol. 2024 Oct 1;10(10):1379-1389. doi: 10.1001/jamaoncol.2024.3044. JAMA Oncol. 2024. PMID: 39145953 Clinical Trial.
Laparoscopic surgery for endometrial cancer is oncologically safe and improves hospital stay duration: a retrospective single-center study over a 16-year period.
Rambow AC, Nikolai M, Jansen P, Rogmans C, Tribian N, Bauerschlag DO, Maass N, van Mackelenbergh MT. Rambow AC, et al. Among authors: van mackelenbergh mt. Arch Gynecol Obstet. 2024 Aug;310(2):1207-1213. doi: 10.1007/s00404-024-07550-x. Epub 2024 May 25. Arch Gynecol Obstet. 2024. PMID: 38789852 Free PMC article.
Decision Coaching for Healthy Women With BRCA1/2 Pathogenic Variants—Findings of the Randomized Controlled EDCP-BRCA Trial.
Stock S, Isselhard A, Shukri A, Kautz-Freimuth S, Redaèlli M, Berger-Höger B, Dikow N, Kiechle M, Köberlein-Neu J, Meisel C, Schmutzler R, Steckelberg A, van Mackelenbergh MT, Vitinius F, Wöckel A, Rhiem K. Stock S, et al. Among authors: van mackelenbergh mt. Dtsch Arztebl Int. 2024 Jun 14;121(12):393-400. doi: 10.3238/arztebl.m2024.0049. Dtsch Arztebl Int. 2024. PMID: 38629689 Free PMC article. Clinical Trial.
Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial.
Williams TM, Schneeweiss A, Jackisch C, Shen C, Weber KE, Fasching PA, Denkert C, Furlanetto J, Heinmöller E, Schmatloch S, Karn T, Szeto CW, van Mackelenbergh MT, Nekljudova V, Stickeler E, Soon-Shiong P, Schem C, Mairinger T, Müller V, Marme F, Untch M, Loibl S. Williams TM, et al. Among authors: van mackelenbergh mt. Clin Cancer Res. 2023 Sep 1;29(17):3384-3394. doi: 10.1158/1078-0432.CCR-23-0362. Clin Cancer Res. 2023. PMID: 37432976 Free PMC article.
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Harbeck N, Fasching PA, Wuerstlein R, Degenhardt T, Lüftner D, Kates RE, Schumacher J, Räth P, Hoffmann O, Lorenz R, Decker T, Reinisch M, Göhler T, Staib P, Gluz O, Schinköthe T, Schmidt M; AGO-B WSG PreCycle investigators (see Appendix 1). Harbeck N, et al. Ann Oncol. 2023 Aug;34(8):660-669. doi: 10.1016/j.annonc.2023.05.003. Epub 2023 May 16. Ann Oncol. 2023. PMID: 37201751 Free article. Clinical Trial.
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
van Mackelenbergh MT, Loibl S, Untch M, Buyse M, Geyer CE Jr, Gianni L, Schneeweiss A, Conte P, Piccart M, Bonnefoi H, Jackisch C, Nekljudova V, Tang G, Valagussa P, Neate C, Gelber R, Poncet C, Squifflet P, Saad ED, Heinzmann D, Denkert C, Rastogi P, Cortes J, Guarneri V, de Azambuja E, Cameron D, Ismael G, Wolmark N, Cortazar P; CTNeoBC project. van Mackelenbergh MT, et al. J Clin Oncol. 2023 Jun 1;41(16):2998-3008. doi: 10.1200/JCO.22.02241. Epub 2023 Apr 19. J Clin Oncol. 2023. PMID: 37075276
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy.
Squifflet P, Saad ED, Loibl S, van Mackelenbergh MT, Untch M, Rastogi P, Gianni L, Schneeweiss A, Conte P, Piccart M, Bonnefoi H, Jackisch C, Nekljudova V, Tang G, Valagussa P, Neate C, Gelber R, Poncet C, Heinzmann D, Denkert C, Geyer CE Jr, Cortes J, Guarneri V, de Azambuja E, Cameron D, Ismael G, Wolmark N, Cortazar P, Buyse M; CTNeoBC Project. Squifflet P, et al. Among authors: van mackelenbergh mt. J Clin Oncol. 2023 Jun 1;41(16):2988-2997. doi: 10.1200/JCO.22.02363. Epub 2023 Mar 28. J Clin Oncol. 2023. PMID: 36977286
Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.
van Mackelenbergh MT, Seither F, Möbus V, O'Shaughnessy J, Martin M, Joensuu H, Untch M, Nitz U, Steger GG, Miralles JJ, Barrios CH, Toi M, Bear HD, Muss H, Reimer T, Nekljudova V, Loibl S. van Mackelenbergh MT, et al. Eur J Cancer. 2022 May;166:185-201. doi: 10.1016/j.ejca.2022.02.003. Epub 2022 Mar 16. Eur J Cancer. 2022. PMID: 35305453
High Antitumor Activity of the Dual Topoisomerase Inhibitor P8-D6 in Breast Cancer.
Flörkemeier I, Steinhauer TN, Hedemann N, Weimer JP, Rogmans C, van Mackelenbergh MT, Maass N, Clement B, Bauerschlag DO. Flörkemeier I, et al. Among authors: van mackelenbergh mt. Cancers (Basel). 2021 Dec 21;14(1):2. doi: 10.3390/cancers14010002. Cancers (Basel). 2021. PMID: 35008166 Free PMC article.
14 results